| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $107.5M | +590.8% |
| SG&A Expense | $26.8M | +78.1% |
| Operating Income | -$224.8M | -414.9% |
| Pre-tax Income | -$218.5M | -362.8% |
| Income Tax | -$9.3M | — |
| Net Income | -$209.1M | -343.0% |
| EPS (Basic) | -$14.49 | -316.4% |
| EPS (Diluted) | -$14.49 | -316.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $352.4M | — |
| Current Assets | $359.1M | +367.6% |
| Total Assets | $451.0M | +167.1% |
| Current Liabilities | $67.3M | +233.7% |
| Total Liabilities | $163.6M | +132.6% |
| Stockholders' Equity | -$253.5M | -461.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$100.0M | -182.7% |
| Capital Expenditures | $43K | +48.3% |
| Investing Cash Flow | -$43K | +99.8% |
| Financing Cash Flow | $378.2M | +205.8% |
| Free Cash Flow | -$100.1M | -182.5% |